Summary
Vertex Pharmaceuticals Incorporated has entered into a significant amendment to its collaboration agreement with the Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT). This April 2011 Amendment provides substantial financial backing from CFFT, up to $75.0 million over approximately five years, to support the development of VX-661, a corrector compound for cystic fibrosis, and other corrector compound discovery efforts. This strategic funding injects crucial capital into Vertex's ongoing research and development for cystic fibrosis therapies, particularly focusing on corrector compounds. While Vertex retains full development and commercialization rights for the compounds, including VX-770, VX-809, and VX-661, the amendment outlines a royalty structure and potential milestone payments to CFFT based on future net sales. Investors should note that this agreement signifies continued partnership and external validation of Vertex's cystic fibrosis program, while also establishing financial obligations tied to the eventual success of these drug candidates.
Key Highlights
- 1Vertex Pharmaceuticals entered into an April 2011 Amendment to its collaboration agreement with Cystic Fibrosis Foundation Therapeutics Incorporated (CFFT).
- 2CFFT will provide up to $75.0 million in financial support over approximately five years.
- 3The funding is designated for development activities of VX-661, a corrector compound, and additional research for new corrector compounds.
- 4Vertex retains all rights to develop and commercialize VX-770, VX-809, VX-661, and other compounds discovered under the collaboration.
- 5The agreement includes a tiered royalty structure on net sales of corrector compounds discovered from 2011 onwards, similar to previous agreements.
- 6Vertex is also obligated to make two one-time commercial milestone payments for potentiator compounds (like VX-770) and two for corrector compounds (like VX-809 or VX-661) upon achieving certain sales levels.
- 7CFFT's funding obligations can be terminated under specific circumstances, which would lead to proportional adjustments in royalty rates and milestones for certain corrector compounds.